A monoclonal antibody against annexin A2 targets stem and progenitor cell fractions in tumors

Volume: 15, Issue: 1, Pages: 101257 - 101257
Published: Jan 1, 2022
Abstract
The involvement of cancer stem cells (CSCs) in driving tumor dormancy and drug resistance is well established. Most therapeutic regimens however are ineffective in targeting these regenerative populations. We report the development and evaluation of a monoclonal antibody, mAb150, which targets the metastasis associated antigen, Annexin A2 (AnxA2) through recognition of a N-terminal epitope. Treatment with mAb150 potentiated re-entry of CSCs into...
Paper Details
Title
A monoclonal antibody against annexin A2 targets stem and progenitor cell fractions in tumors
Published Date
Jan 1, 2022
Volume
15
Issue
1
Pages
101257 - 101257
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.